Hwang to Sue U.S. Collaborator Over Stem Cell Patent
By Chosun Ilbo,
Chosun Ilbo
| 02. 14. 2006
Lawyers for the disgraced cloning scientist Hwang Woo-suk on Monday decided to take legal action against Hwang_s one-time collaborator Prof. Gerald Schatten, who is insisting on his right to a stem-cell technology patent. Schatten, of the University of Pittsburgh, is a co-author of Hwang_s discredited 2005 Science paper on patient-specific stem cells.
Hwang_s lawyers asked Seoul National University, to which Hwang transferred his right to apply for stem-cell related patents, to return the right to the scientist.
They said SNU was attempting to cancel the patent application since Hwang_s research results were fabricated, but Schatten, _who has done nothing to create stem cells,_ had no such compunction and was trying to make the patents for related technology his own. Their plan is to take legal action against Schatten once the university returns the rights.
Related Articles
By David Jensen, California Stem Cell Report | 02.10.2026
Touchy issues involving accusations that California’s $12 billion gene and stem cell research agency is pushing aside “good science” in favor of new priorities and preferences will be aired again in late March at a public meeting in Sacramento.
The...
By Roni Caryn Rabin, The New York Times | 01.22.2026
The National Institutes of Health said on Thursday it is ending support for all research that makes use of human fetal tissue, eliminating funding for projects both within and outside of the agency.
A ban instituted in June 2019 by...
By David Jensen, The California Stem Cell Report | 12.11.2025
California’s stem cell and gene therapy agency today approved spending $207 million more on training and education, sidestepping the possibility of using the cash to directly support revolutionary research that has been slashed and endangered by the Trump administration.
Directors...
By Frankie Fattorini, Pharmaceutical Technology | 12.02.2025
Próspera, a charter city on Roatán island in Honduras, hosts two biotechs working to combat ageing through gene therapy, as the organisation behind the city advertises its “flexible” regulatory jurisdiction to attract more developers.
In 2021, Minicircle set up a...
